News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Capstone Therapeutics (CAPS) Announces Pre-Clinical Results With AZX100 in Radiation and Bleomycin Models of Pulmonary Fibrosis; Pulmonary Anti-Fibrotic Effect Demonstrated



7/6/2011 10:18:26 AM

TEMPE, Ariz., July 6, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced results from a pre-clinical study of AZX100 in a rodent model of radiation-induced pulmonary fibrosis.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES